ImmunityBio Investors Urged to Seek Lead Role in Suit After FDA Rebuke Over Anktiva Ads

Overview

• Plaintiff firms issued fresh notices on April 24–25 inviting ImmunityBio shareholders to seek lead‑plaintiff status in a federal securities class action.
• The litigation follows publication on March 24 of an FDA warning letter that called a TV ad and a podcast for Anktiva false or misleading.
• The FDA said the materials implied Anktiva could cure or prevent all cancer and left out key limits of its approved use.
• After that disclosure, ImmunityBio shares fell about 21% to close at $7.42, erasing nearly $2 billion in market value.
• Complaints, including Douglas v. ImmunityBio in the Central District of California, allege Patrick Soon‑Shiong overstated Anktiva’s abilities during a class period of January 19 to March 24, 2026.